Agreement signed with the University of Pennsylvania Hospital for Clinical Study on Prostate Cancer Treatment

SpectraCure has signed an agreement with the University of Pennsylvania Hospital ("Penn Hospital") in Philadelphia, USA. The agreement concerns clinical studies for treatment of patients with recurrent prostate cancer with the company's photodynamic tumor therapy technique (PDT). Penn Hospital will be involved in the Phase 1 study that is also conducted at the Princess Margaret Cancer Center in Toronto, Canada. Thereafter, a continuation of a phase 2 study is planned.

As previously announced, University College London Hospital in London, UK, will also participate in the Phase 1 study. This means that recruitment of patients will run parallel in Philadelphia, London and Toronto, the results will then be compiled.
– It is very pleasing that we now have an agreement with Penn in place, comments CEO Masoud Khayyami. Secondly, it is important to be able to keep a fast pace in the clinical program in the future, and it is strategically important for commercialization and approval from the authorities to have the study in the United States. Penn Hospital is a highly reputed hospital.

For further information, please contact:
SpectraCure AB publ, CEO, Masoud Khayyami, phone: +46 (0) 70 815 21 90

This information is information that SpectraCure AB is required to disclose under the EU Market Abuse Regulation. The information was provided, through the contact of the above contact person, for publication on April 23th, 2018.

SpectraCure in short

SpectraCure was founded in 2003 as a spin off from Lund University departments for medical laser applications and physics. The company focuses on cancer treatments using medical systems with laser light sources and reactive drugs, which is referred to as "Interstitial Photodynamic Therapy", PDT, a treatment methodology suitable for internal solid tumours of various kind, e.g. prostate and abdominal salivary glands, but also other indications such as cancer tumours in the head and neck region

Release

SpectraCure is developing the future systems for the treatment of internal solid cancer tumours. The goal of the proprietary and patented treatment system is to eliminate deep-seated cancer tumours and prolong the survival of cancer patients while maintaining their quality of life. When prostate cancer recurs, there are often no established treatment options other than lifelong hormone therapy, with its associated side effects. 

Facebook Linkedin Envelope